3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Status
Terminated
1
Recruiting
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Thoracic
2
Head & Neck
1
Conditions
Carcinoma, Non-Small-Cell Lung
106
Lung Neoplasms
41
Neoplasms
13
Neoplasm Metastasis
11
Colorectal Neoplasms
9
Parkinson Disease 4, Autosomal Dominant Lewy Body
6
Pancreatic Neoplasms
6
Carcinoma
6
Mesothelioma, Malignant
5
Mesothelioma
5
Ovarian Neoplasms
4
Meningeal Carcinomatosis
4
Melanoma
4
Colonic Neoplasms
4
Advanced Solid Tumors
4
Rectal Neoplasms
3
Neoplasms by Site
3
Lung Diseases
3
Carcinoma, Bronchogenic
3
Adenocarcinoma of Lung
3
Adenocarcinoma
3
Uterine Cervical Neoplasms
2
Thoracic Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Small Cell Lung Carcinoma
2
Respiratory Tract Neoplasms
2
Respiratory Tract Diseases
2
Non-squamous Non-small Cell Lung Cancer
2
Non-Small Cell Lung Cancer Metastatic
2
Non Small Cell Lung Carcinoma NSCLC
2
Interventions
Carboplatin
3
pembrolizumab
2
durvalumab
2
Pemetrexed
2
Cisplatin
2
selpercatinib
1
repotrectinib
1
pralsetinib
1
ceralasertib
1
Paclitaxel
1
Gemcitabine
1
Bevacizumab
1
130-nm albumin-bound paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Respiratory Tract Diseases
×
Pemetrexed
×
90 days
×
Clear all
NCT06119581
2026-06-03
SUNRAY-01
Eli Lilly and Company
Phase 3
Recruiting
1,264 enrolled
NCT04222972
2026-03-05
AcceleRET-Lung
Hoffmann-La Roche
Phase 3
Terminated
223 enrolled
18 charts